APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phage Therapy

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

Selected research

Market Outlook & Growth Opportunities

Global Phage Therapy Market Outlook and Growth Opportunities 2026

29 December 2025218 pages

Choose your research edition.

Industry ResearchPhage Therapy Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Phage Therapy Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Phage Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phage Therapy Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Phage Therapy Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

The major players in global Phage Therapy market include NPO Microgen, Proteon Pharmaceuticals, Phagelux, etc. The top 3 players occupy about 25% shares of the global market. North America and Europe are main markets, they occupy about 60% of the global market. DsDNA Bacteriophage is the main type, with a share over 90%. Animal Health is the main application, which holds a share about 55%.

This report provides an overview of the global Phage Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Phage Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phage Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Phage Therapy market.

Phage Therapy Segment by Company

NPO Microgen

Proteon Pharmaceuticals

Phagelux

Intralytix

Micreos

Eliava BioPreparations

Locus Biosciences,Inc

Pharmex Group,LLC

Pherecydes Pharma

APS Biocontrol Ltd. (APS)

Qingdao Phagepharm Bio-tech

Fixed-Phage Limited

Zeptometrix

Phage International, Inc.

MicroMir

iNtODEWORLD, Inc.

NEXTBIOTICS

Armata Pharmaceuticals, Inc.

Innophage

Adaptive Phage Therapeutics

TechnoPhage

Phage Therapy Segment by Type

DsDNA Bacteriophage

SsDNA Bacteriophage

SsRNA Bacteriophage

Others

Phage Therapy Segment by Application

Animal Health

Aquaculture

Agriculture

Food Industry

Human Health

Others

Phage Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Phage Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Phage Therapy key companies, revenue, market share, and recent developments.

3. To split the Phage Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Phage Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Phage Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Phage Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phage Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phage Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phage Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Phage Therapy industry.

Chapter 3: Detailed analysis of Phage Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Phage Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Phage Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Phage Therapy Industry Trends Table 2. Phage Therapy Industry Drivers Table 3. Phage Therapy Industry Opportunities and Challenges Table 4. Phage Therapy Industry Restraints Table 5. Global Phage Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Phage Therapy Revenue Share by Company (2021-2026) Table 7. Global Phage Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Phage Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Phage Therapy Company, Product Type & Application Table 10. Global Phage Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Phage Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DsDNA Bacteriophage Table 15. Significant Companies of SsDNA Bacteriophage Table 16. Significant Companies of SsRNA Bacteriophage Table 17. Significant Companies of Others Table 18. Global Phage Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Phage Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Phage Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Phage Therapy Sales Value Share by Type (2021-2026) Table 22. Global Phage Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Animal Health Table 24. Significant Companies of Aquaculture Table 25. Significant Companies of Agriculture Table 26. Significant Companies of Food Industry Table 27. Significant Companies of Human Health Table 28. Significant Companies of Others Table 29. Global Phage Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Phage Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Phage Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Phage Therapy Sales Value Share by Application (2021-2026) Table 33. Global Phage Therapy Sales Value Share by Application (2027-2032) Table 34. Global Phage Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Phage Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Phage Therapy Sales Value Share by Region (2021-2026) Table 37. Global Phage Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Phage Therapy Sales Value Share by Region (2027-2032) Table 39. Global Phage Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Phage Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Phage Therapy Sales Value Market Share by Country (2021-2026) Table 42. Global Phage Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Phage Therapy Sales Value Market Share by Country (2027-2032) Table 44. NPO Microgen Company Information Table 45. NPO Microgen Business Overview Table 46. NPO Microgen Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. NPO Microgen Phage Therapy Product Portfolio Table 48. NPO Microgen Recent Development Table 49. Proteon Pharmaceuticals Company Information Table 50. Proteon Pharmaceuticals Business Overview Table 51. Proteon Pharmaceuticals Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Proteon Pharmaceuticals Phage Therapy Product Portfolio Table 53. Proteon Pharmaceuticals Recent Development Table 54. Phagelux Company Information Table 55. Phagelux Business Overview Table 56. Phagelux Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Phagelux Phage Therapy Product Portfolio Table 58. Phagelux Recent Development Table 59. Intralytix Company Information Table 60. Intralytix Business Overview Table 61. Intralytix Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Intralytix Phage Therapy Product Portfolio Table 63. Intralytix Recent Development Table 64. Micreos Company Information Table 65. Micreos Business Overview Table 66. Micreos Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Micreos Phage Therapy Product Portfolio Table 68. Micreos Recent Development Table 69. Eliava BioPreparations Company Information Table 70. Eliava BioPreparations Business Overview Table 71. Eliava BioPreparations Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Eliava BioPreparations Phage Therapy Product Portfolio Table 73. Eliava BioPreparations Recent Development Table 74. Locus Biosciences,Inc Company Information Table 75. Locus Biosciences,Inc Business Overview Table 76. Locus Biosciences,Inc Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Locus Biosciences,Inc Phage Therapy Product Portfolio Table 78. Locus Biosciences,Inc Recent Development Table 79. Pharmex Group,LLC Company Information Table 80. Pharmex Group,LLC Business Overview Table 81. Pharmex Group,LLC Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pharmex Group,LLC Phage Therapy Product Portfolio Table 83. Pharmex Group,LLC Recent Development Table 84. Pherecydes Pharma Company Information Table 85. Pherecydes Pharma Business Overview Table 86. Pherecydes Pharma Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pherecydes Pharma Phage Therapy Product Portfolio Table 88. Pherecydes Pharma Recent Development Table 89. APS Biocontrol Ltd. (APS) Company Information Table 90. APS Biocontrol Ltd. (APS) Business Overview Table 91. APS Biocontrol Ltd. (APS) Phage Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. APS Biocontrol Ltd. (APS) Phage Therapy Product Portfolio Table 93. APS Biocontrol Ltd. (APS) Recent Development Table 94. Qingdao Phagepharm Bio-tech Company Information Table 95. Qingdao Phagepharm Bio-tech Business Overview Table 96. Qingdao Phagepharm Bio-tech Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Qingdao Phagepharm Bio-tech Phage Therapy Product Portfolio Table 98. Qingdao Phagepharm Bio-tech Recent Development Table 99. Fixed-Phage Limited Company Information Table 100. Fixed-Phage Limited Business Overview Table 101. Fixed-Phage Limited Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Fixed-Phage Limited Phage Therapy Product Portfolio Table 103. Fixed-Phage Limited Recent Development Table 104. Zeptometrix Company Information Table 105. Zeptometrix Business Overview Table 106. Zeptometrix Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Zeptometrix Phage Therapy Product Portfolio Table 108. Zeptometrix Recent Development Table 109. Phage International, Inc. Company Information Table 110. Phage International, Inc. Business Overview Table 111. Phage International, Inc. Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Phage International, Inc. Phage Therapy Product Portfolio Table 113. Phage International, Inc. Recent Development Table 114. MicroMir Company Information Table 115. MicroMir Business Overview Table 116. MicroMir Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. MicroMir Phage Therapy Product Portfolio Table 118. MicroMir Recent Development Table 119. iNtODEWORLD, Inc. Company Information Table 120. iNtODEWORLD, Inc. Business Overview Table 121. iNtODEWORLD, Inc. Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. iNtODEWORLD, Inc. Phage Therapy Product Portfolio Table 123. iNtODEWORLD, Inc. Recent Development Table 124. NEXTBIOTICS Company Information Table 125. NEXTBIOTICS Business Overview Table 126. NEXTBIOTICS Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. NEXTBIOTICS Phage Therapy Product Portfolio Table 128. NEXTBIOTICS Recent Development Table 129. Armata Pharmaceuticals, Inc. Company Information Table 130. Armata Pharmaceuticals, Inc. Business Overview Table 131. Armata Pharmaceuticals, Inc. Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Armata Pharmaceuticals, Inc. Phage Therapy Product Portfolio Table 133. Armata Pharmaceuticals, Inc. Recent Development Table 134. Innophage Company Information Table 135. Innophage Business Overview Table 136. Innophage Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Innophage Phage Therapy Product Portfolio Table 138. Innophage Recent Development Table 139. Adaptive Phage Therapeutics Company Information Table 140. Adaptive Phage Therapeutics Business Overview Table 141. Adaptive Phage Therapeutics Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Adaptive Phage Therapeutics Phage Therapy Product Portfolio Table 143. Adaptive Phage Therapeutics Recent Development Table 144. TechnoPhage Company Information Table 145. TechnoPhage Business Overview Table 146. TechnoPhage Phage Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. TechnoPhage Phage Therapy Product Portfolio Table 148. TechnoPhage Recent Development Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Phage Therapy Product Image Figure 2. Global Phage Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phage Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Phage Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DsDNA Bacteriophage Image Figure 8. SsDNA Bacteriophage Image Figure 9. SsRNA Bacteriophage Image Figure 10. Others Image Figure 11. Global Phage Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Phage Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Phage Therapy Sales Value Share by Type (2021-2032) Figure 14. Animal Health Image Figure 15. Aquaculture Image Figure 16. Agriculture Image Figure 17. Food Industry Image Figure 18. Human Health Image Figure 19. Others Image Figure 20. Global Phage Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Phage Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Phage Therapy Sales Value Share by Application (2021-2032) Figure 23. Global Phage Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Phage Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Phage Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. North America Phage Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Phage Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Phage Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Phage Therapy Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Phage Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Phage Therapy Sales Value (2021-2032) & (US$ Million) Figure 32. South America Phage Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Phage Therapy Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Phage Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Phage Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Phage Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Phage Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • DsDNA Bacteriophage
  • SsDNA Bacteriophage
  • SsRNA Bacteriophage
  • Others
Applications
  • Animal Health
  • Aquaculture
  • Agriculture
  • Food Industry
  • Human Health
  • Others
Companies covered
  • NPO Microgen
  • Proteon Pharmaceuticals
  • Phagelux
  • Intralytix
  • Micreos
  • Eliava BioPreparations
  • Locus Biosciences,Inc
  • Pharmex Group,LLC
  • Pherecydes Pharma
  • APS Biocontrol Ltd. (APS)
  • Qingdao Phagepharm Bio-tech
  • Fixed-Phage Limited
  • Zeptometrix
  • Phage International, Inc.
  • MicroMir
  • iNtODEWORLD, Inc.
  • NEXTBIOTICS
  • Armata Pharmaceuticals, Inc.
  • Innophage
  • Adaptive Phage Therapeutics
  • TechnoPhage

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phage Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phage Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Phage Therapy Market Dynamics
  1. 2.1 Phage Therapy Industry Trends
  2. 2.2 Phage Therapy Industry Drivers
  3. 2.3 Phage Therapy Industry Opportunities and Challenges
  4. 2.4 Phage Therapy Industry Restraints
3 Phage Therapy Market by Company
  1. 3.1 Global Phage Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Phage Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Phage Therapy Company Ranking (2024-2026)
  4. 3.4 Global Phage Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Phage Therapy Company Product Type and Application
  6. 3.6 Global Phage Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Phage Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Phage Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Phage Therapy Market by Type
  1. 4.1 Phage Therapy Type Introduction
  2. 4.1.1 DsDNA Bacteriophage
  3. 4.1.2 SsDNA Bacteriophage
  4. 4.1.3 SsRNA Bacteriophage
  5. 4.1.4 Others
  6. 4.2 Global Phage Therapy Sales Value by Type
  7. 4.2.1 Global Phage Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Phage Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Phage Therapy Sales Value Share by Type (2021-2032)
5 Phage Therapy Market by Application
  1. 5.1 Phage Therapy Application Introduction
  2. 5.1.1 Animal Health
  3. 5.1.2 Aquaculture
  4. 5.1.3 Agriculture
  5. 5.1.4 Food Industry
  6. 5.1.5 Human Health
  7. 5.1.6 Others
  8. 5.2 Global Phage Therapy Sales Value by Application
  9. 5.2.1 Global Phage Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Phage Therapy Sales Value by Application (2021-2032)
  11. 5.2.3 Global Phage Therapy Sales Value Share by Application (2021-2032)
6 Phage Therapy Regional Value Analysis
  1. 6.1 Global Phage Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phage Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Phage Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Phage Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phage Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Phage Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Phage Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Phage Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Phage Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Phage Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Phage Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Phage Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Phage Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Phage Therapy Sales Value Share by Country, 2025 VS 2032
7 Phage Therapy Country-level Value Analysis
  1. 7.1 Global Phage Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Phage Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Phage Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Phage Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Phage Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Phage Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Phage Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Phage Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Phage Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Phage Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Phage Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Phage Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Phage Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Phage Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Phage Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Phage Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Phage Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Phage Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Phage Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Phage Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Phage Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Phage Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Phage Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Phage Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Phage Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Phage Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Phage Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Phage Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Phage Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Phage Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Phage Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Phage Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Phage Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Phage Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Phage Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Phage Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Phage Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Phage Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Phage Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Phage Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Phage Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Phage Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Phage Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Phage Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Phage Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Phage Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Phage Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Phage Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Phage Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Phage Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Phage Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Phage Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Phage Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Phage Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Phage Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Phage Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Phage Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Phage Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Phage Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Phage Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Phage Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Phage Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Phage Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Phage Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Phage Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Phage Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Phage Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Phage Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Phage Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Phage Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Phage Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Phage Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Phage Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Phage Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Phage Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Phage Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Phage Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Phage Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Phage Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Phage Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Phage Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Phage Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Phage Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Phage Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Phage Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Phage Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Phage Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Phage Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 NPO Microgen
  2. 8.1.1 NPO Microgen Company Information
  3. 8.1.2 NPO Microgen Business Overview
  4. 8.1.3 NPO Microgen Phage Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 NPO Microgen Phage Therapy Product Portfolio
  6. 8.1.5 NPO Microgen Recent Developments
  7. 8.2 Proteon Pharmaceuticals
  8. 8.2.1 Proteon Pharmaceuticals Company Information
  9. 8.2.2 Proteon Pharmaceuticals Business Overview
  10. 8.2.3 Proteon Pharmaceuticals Phage Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Proteon Pharmaceuticals Phage Therapy Product Portfolio
  12. 8.2.5 Proteon Pharmaceuticals Recent Developments
  13. 8.3 Phagelux
  14. 8.3.1 Phagelux Company Information
  15. 8.3.2 Phagelux Business Overview
  16. 8.3.3 Phagelux Phage Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Phagelux Phage Therapy Product Portfolio
  18. 8.3.5 Phagelux Recent Developments
  19. 8.4 Intralytix
  20. 8.4.1 Intralytix Company Information
  21. 8.4.2 Intralytix Business Overview
  22. 8.4.3 Intralytix Phage Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Intralytix Phage Therapy Product Portfolio
  24. 8.4.5 Intralytix Recent Developments
  25. 8.5 Micreos
  26. 8.5.1 Micreos Company Information
  27. 8.5.2 Micreos Business Overview
  28. 8.5.3 Micreos Phage Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Micreos Phage Therapy Product Portfolio
  30. 8.5.5 Micreos Recent Developments
  31. 8.6 Eliava BioPreparations
  32. 8.6.1 Eliava BioPreparations Company Information
  33. 8.6.2 Eliava BioPreparations Business Overview
  34. 8.6.3 Eliava BioPreparations Phage Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eliava BioPreparations Phage Therapy Product Portfolio
  36. 8.6.5 Eliava BioPreparations Recent Developments
  37. 8.7 Locus Biosciences,Inc
  38. 8.7.1 Locus Biosciences,Inc Company Information
  39. 8.7.2 Locus Biosciences,Inc Business Overview
  40. 8.7.3 Locus Biosciences,Inc Phage Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Locus Biosciences,Inc Phage Therapy Product Portfolio
  42. 8.7.5 Locus Biosciences,Inc Recent Developments
  43. 8.8 Pharmex Group,LLC
  44. 8.8.1 Pharmex Group,LLC Company Information
  45. 8.8.2 Pharmex Group,LLC Business Overview
  46. 8.8.3 Pharmex Group,LLC Phage Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pharmex Group,LLC Phage Therapy Product Portfolio
  48. 8.8.5 Pharmex Group,LLC Recent Developments
  49. 8.9 Pherecydes Pharma
  50. 8.9.1 Pherecydes Pharma Company Information
  51. 8.9.2 Pherecydes Pharma Business Overview
  52. 8.9.3 Pherecydes Pharma Phage Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pherecydes Pharma Phage Therapy Product Portfolio
  54. 8.9.5 Pherecydes Pharma Recent Developments
  55. 8.10 APS Biocontrol Ltd. (APS)
  56. 8.10.1 APS Biocontrol Ltd. (APS) Company Information
  57. 8.10.2 APS Biocontrol Ltd. (APS) Business Overview
  58. 8.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 APS Biocontrol Ltd. (APS) Phage Therapy Product Portfolio
  60. 8.10.5 APS Biocontrol Ltd. (APS) Recent Developments
  61. 8.11 Qingdao Phagepharm Bio-tech
  62. 8.11.1 Qingdao Phagepharm Bio-tech Company Information
  63. 8.11.2 Qingdao Phagepharm Bio-tech Business Overview
  64. 8.11.3 Qingdao Phagepharm Bio-tech Phage Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Qingdao Phagepharm Bio-tech Phage Therapy Product Portfolio
  66. 8.11.5 Qingdao Phagepharm Bio-tech Recent Developments
  67. 8.12 Fixed-Phage Limited
  68. 8.12.1 Fixed-Phage Limited Company Information
  69. 8.12.2 Fixed-Phage Limited Business Overview
  70. 8.12.3 Fixed-Phage Limited Phage Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fixed-Phage Limited Phage Therapy Product Portfolio
  72. 8.12.5 Fixed-Phage Limited Recent Developments
  73. 8.13 Zeptometrix
  74. 8.13.1 Zeptometrix Company Information
  75. 8.13.2 Zeptometrix Business Overview
  76. 8.13.3 Zeptometrix Phage Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Zeptometrix Phage Therapy Product Portfolio
  78. 8.13.5 Zeptometrix Recent Developments
  79. 8.14 Phage International, Inc.
  80. 8.14.1 Phage International, Inc. Company Information
  81. 8.14.2 Phage International, Inc. Business Overview
  82. 8.14.3 Phage International, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Phage International, Inc. Phage Therapy Product Portfolio
  84. 8.14.5 Phage International, Inc. Recent Developments
  85. 8.15 MicroMir
  86. 8.15.1 MicroMir Company Information
  87. 8.15.2 MicroMir Business Overview
  88. 8.15.3 MicroMir Phage Therapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 MicroMir Phage Therapy Product Portfolio
  90. 8.15.5 MicroMir Recent Developments
  91. 8.16 iNtODEWORLD, Inc.
  92. 8.16.1 iNtODEWORLD, Inc. Company Information
  93. 8.16.2 iNtODEWORLD, Inc. Business Overview
  94. 8.16.3 iNtODEWORLD, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 iNtODEWORLD, Inc. Phage Therapy Product Portfolio
  96. 8.16.5 iNtODEWORLD, Inc. Recent Developments
  97. 8.17 NEXTBIOTICS
  98. 8.17.1 NEXTBIOTICS Company Information
  99. 8.17.2 NEXTBIOTICS Business Overview
  100. 8.17.3 NEXTBIOTICS Phage Therapy Revenue and Gross Margin (2021-2026)
  101. 8.17.4 NEXTBIOTICS Phage Therapy Product Portfolio
  102. 8.17.5 NEXTBIOTICS Recent Developments
  103. 8.18 Armata Pharmaceuticals, Inc.
  104. 8.18.1 Armata Pharmaceuticals, Inc. Company Information
  105. 8.18.2 Armata Pharmaceuticals, Inc. Business Overview
  106. 8.18.3 Armata Pharmaceuticals, Inc. Phage Therapy Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Armata Pharmaceuticals, Inc. Phage Therapy Product Portfolio
  108. 8.18.5 Armata Pharmaceuticals, Inc. Recent Developments
  109. 8.19 Innophage
  110. 8.19.1 Innophage Company Information
  111. 8.19.2 Innophage Business Overview
  112. 8.19.3 Innophage Phage Therapy Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Innophage Phage Therapy Product Portfolio
  114. 8.19.5 Innophage Recent Developments
  115. 8.20 Adaptive Phage Therapeutics
  116. 8.20.1 Adaptive Phage Therapeutics Company Information
  117. 8.20.2 Adaptive Phage Therapeutics Business Overview
  118. 8.20.3 Adaptive Phage Therapeutics Phage Therapy Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Adaptive Phage Therapeutics Phage Therapy Product Portfolio
  120. 8.20.5 Adaptive Phage Therapeutics Recent Developments
  121. 8.21 TechnoPhage
  122. 8.21.1 TechnoPhage Company Information
  123. 8.21.2 TechnoPhage Business Overview
  124. 8.21.3 TechnoPhage Phage Therapy Revenue and Gross Margin (2021-2026)
  125. 8.21.4 TechnoPhage Phage Therapy Product Portfolio
  126. 8.21.5 TechnoPhage Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst